Status:
COMPLETED
Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Waldenstrom Macroglobulinemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is designed to evaluate the efficacy and toxicity of Bortezomib , an inhibitor of proteasome used in multiple myeloma, in patients with advanced Waldenström's Macroglobulinemia disease.
Detailed Description
Open, prospective, multicenter, non controlled phase IIA trial Primary objectives Evaluation of the efficacy and safety of Velcade in monotherapy for patients with advanced stage Waldenström Macroglo...
Eligibility Criteria
Inclusion
- ● Established diagnosis of Waldenström macroglobulinemia (the 2nd Workshop on Waldenstrom's macroglobulinemia)
- Patient must have had 1 (or 2) lines of chemotherapy containing alkylating agent and/or Fludarabine :and /or monoclonal antibody and must have :
- Life expectancy \> 3 months
- Age \> 18 years
- ECOG performance status 0-1-2
- ANC \> 1 x 109/L
- Creatinine clearance, calculated according to the formula of cockcroft and Gault \> 40 ml/min
- Total bilirubin \< 2x ULN
- ASAT, ALAT \< 2x ULN
- A negative serum pregnancy test one week prior to treatment must be available both for pre-menopausal women and for women who are \< 2 years after the onset of menopause
- Adequate contraceptive methods for males and pre-menopausal females for 6 months after treatment discontinuation.
- Written informed consent
- Platelets\> 100X 109
Exclusion
- Active secondary malignancy or chemotherapy/radiotherapy for any neoplastic disease other than Waldenström macroglobulinemia prior to the study
- Medical condition requiring the long-term (estimated to be more than one month) use of oral corticosteroids
- Patients with active bacterial, viral or fungal infection
- Known infection with HIV, Hepatitis B (except post vaccinal profile) or C
- Treatment with any, other investigational agent or participating in another trial within 30 days prior to entering this study
- Lactation/pregnancy
- Concurrent severe diseases which exclude the administration of therapy heart insufficiency NYHA grade III/IV, LEVF \< 50% and or RF \< 30%, myocardial infarction within the past 6 months prior to study
- Severe pulmonary or heart problems (acute diffuse pulmonary and pericardial disease)
- Severe chronic obstructive lung disease with hypoxemia
- Severe diabetes mellitus
- Hypertension difficult to control
- Impaired renal function with creatinine clearance \< 40 ml/min according to the formula of Cockcroft and Gault
- Cerebral dysfunction
- Richter's syndrome
- Neuropathy\> grade 1
- Positive Beta HCG
- Severe Hepato cellular alteration
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00777738
Start Date
October 1 2008
End Date
August 1 2012
Last Update
January 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital La Pitie Salpetriere
Paris, France, 75013